Table 1 Studies documenting duration of MRSA colonization meeting inclusion criteria
Author year [ref] | Study ID | Design | Country | Year of study | Subject description | Screening site | Screening method | Latest documented follow up (weeks) | N | Lost to follow up (N) | Clearance defined | Weeks to documented clearance | % cleared |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanford 1994 [11] | A | Retrospective cohort | USA | 1989-1991 | Hospitalized patients | Nares, axillae, perineum/ groin, wound, sputum, tracheal aspirate | CX; T | 240 | 36 | * | 2 negative CX | 172 | 50%†|
Mulhausen 1996 [12] | B | Prospective cohort | USA | 1991-2 | Residents at LTCFs | Nares | CX | 52 | 47 | 34 | 1 negative CX on two separate samplings | 52 | 13% |
O’Sullivan 2000 [13] | C | Prospective cohort | Ireland | 1994-5 | Residents at LTCFs | Nares, throat, hairline, axillae, groin, perineum, skin lesions | CX; T | 39 | 65 | 14 | 1 negative CX | 26 | 49% |
Scanvic 2001 [14] | D | Prospective cohort | France | 1998 | Hospitalized patients | Nares, skin, axillae, groin | CX; T | 36 (a) | 78 | * | 4 negative CX obtained from 2 sites | 37 | 50%†|
Ellis 2004 [15] | E | Prospective cohort | USA | 2003 | US Army personnel | Nares | CX; T | 13 | 24 | * | 1 negative CX | 9 | 67% |
Cretnik 2005 [16] | F | Prospective cohort | Slovenia | 2001-2 | Residents and HCW at LTCFs | Nares, skin lesions, axillae, groin | CX; T | 13 | 12 | 2 | 2 negative CX from 2 sites on 3 separate samplings | 13 | 33% |
Vriens 2005 [17] | G | Prospective cohort | Netherlands | 1991-2001 | Hospitalized patients | Nares, throat, perineum, wounds, skin lesions, urine and sputum | CX; PCR | 104 | 57 | 21 | All negative CX from up to 7 sites on 3 separate samplings | 104 | 46% |
Marschall 2006 [18] | H | Retrospective cohort | Switzerland | 2000-3 | Hospitalized patients | Nares, groin, skin lesions, tracheal secretions, urine | CX; T | 231 | 80 | * | All negative CX from up to 6 sites on 2 separate samplings | 85 | 50%†|
Ellis 2007 [19] | I | RCT | USA | 2005 | US Army personnel | Nares | CX; T | 16 | 66 | 1 | 1 negative CX | 16 | 64% |
Simor 2007 [20] | J | RCT | Canada | 2000-3 | Hospitalized patients | Nares, perineum, skin lesions, catheter sites | CX; T | 34 | 35 | 26 | 1 negative CX on 2 separate samplings | 13 | 23% |
Wendt 2007 [21] | K | RCT | Germany | 2001-4 | Hospitalized patients and residents at LTCFs | Nares, throat, groin, perineum, skin defects, any previously colonized site | CX; T | 13 | 58 | 3 | All negative CX at up to 7 sites on 5 separate samplings | 4 | 12% |
Lucet 2009 [22] | L | Prospective cohort | France | 2003-4 | Hospitalized patients discharged to home care | Nares, chronic skin lesions | CX | 52 | 148 | 44 | 1 negative CX on 2 separate samplings | 52 | 51% |
Robicsek 2009 [23] | M | Retrospective cohort | USA | 2006-7 | Hospitalized patients | Nares | PCR | 208 | 824 | * | 1 negative PCR | 208 | 79% |
Lautenbach 2010 [24] | N | Prospective cohort | USA | 2008 | Ambulatory patients and household contacts | Nares, axilla, throat; groin and perineum | CX; PCR; T | 14 | 11 | 0 | All negative cultures from up to 5 sites on 6 separate collections | 14 | 73% |
Manzur 2010 [25] | O | Prospective cohort | Spain | 2005-7 | Residents at LTCFs | Nares, decubitus ulcers | CX; T | 77 | 231 | 104 | 1 negative CX on 2 separate collections | 77 | 27% |
Van Velzen 2011 [26] | P | Retrospective cohort | Scotland | 2010 | Hospitalized patients | Nares, perineum, axillae, throat, wounds and devices | CX; PCR; T | 4 | 32 | 0 | All negative cultures from up to 6 sites on 2 separate occasions | 1 | 25% |